×
About 8,070 results

ALLMedicine™ Myeloma Center

Research & Reviews  3,147 results

Aberrant ENPP2 expression promotes tumor progression in multiple myeloma.
https://doi.org/10.1080/10428194.2021.2010055
Leukemia & Lymphoma; Li Y, Zhang L et. al.

Dec 2nd, 2021 - Ectonucleotide pyrophosphatase/phosphodiesterase 2 (ENPP2) has been recently linked to tumor development. However, its role in modulating multiple myeloma (MM) disease progression remains unclear. Here, we demonstrated that CD138+ cells isolated f...

Subclone-specific microenvironmental impact and drug response in refractory multiple my...
https://doi.org/10.1038/s41467-021-26951-z
Nature Communications; Tirier SM, Mallm JP et. al.

Dec 1st, 2021 - Virtually all patients with multiple myeloma become unresponsive to treatment over time. Relapsed/refractory multiple myeloma (RRMM) is accompanied by the clonal evolution of myeloma cells with heterogeneous genomic aberrations and profound change...

see more →

Guidelines  10 results

Mobilization and Exercise Intervention for Patients With Multiple Myeloma: Clinical Pra...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781094
Physical Therapy; Jeevanantham D, Rajendran V et. al.

Sep 26th, 2020 - Individuals with multiple myeloma (MM) often have reduced functional performance due to the cancer itself or as a direct side effect of cancer treatments. Physical therapy is a part of cancer rehabilitation; however, no guidelines are available to...

Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patien...
https://doi.org/10.1111/joim.12882
Journal of Internal Medicine; Bringhen S, Milan A et. al.

Feb 7th, 2019 - The novel proteasome inhibitor carfilzomib alone or in combination with other agents is already one of the standard therapies for relapsed and/or refractory multiple myeloma (MM) patients and produces impressive response rates in newly diagnosed M...

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2017.0023
Journal of the National Comprehensive Cancer Network : JN... Kumar SK, Callander NS et. al.

Feb 12th, 2017 - Multiple myeloma (MM) is caused by the neoplastic proliferation of plasma cells. These neoplastic plasma cells proliferate and produce monoclonal immunoglobulin in the bone marrow causing skeletal damage, a hallmark of multiple myeloma. Other MM-r...

Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891187
Journal of the National Comprehensive Cancer Network : JN... Anderson KC, Alsina M et. al.

Nov 11th, 2015 - Multiple myeloma (MM) is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. Recent statistics from the American Cancer Society indicate that the incidence of MM is increasing. The N...

American Society of Blood and Marrow Transplantation, European Society of Blood and Mar...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4757494
Biology of Blood and Marrow Transplantation : Journal of ... Giralt S, Garderet L et. al.

Oct 3rd, 2015 - In contrast to the upfront setting in which the role of high-dose therapy with autologous hematopoietic cell transplantation (HCT) as consolidation of a first remission in patients with multiple myeloma (MM) is well established, the role of high-d...

see more →

Drugs  10 results see all →

News  55 results

New Trials in Lymphoma and MM: Could Your Patient Benefit?
https://www.medscape.com/viewarticle/962201

Nov 3rd, 2021 - A number of late-phase clinical trials in lymphoma and multiple myeloma (MM) have opened in recent months. Maybe one of your patients could benefit from being enrolled? Untreated peripheral T-cell lymphoma. Adult patients with peripheral T-cell ly...

Multiple Myeloma Clinical Practice Guidelines (EHA/ESMO, 2021)
https://reference.medscape.com/viewarticle/948408

Apr 1st, 2021 - Clinical guidelines on the management of multiple myeloma (MM) were published in February 2021 by the European Hematology Association and the European Society for Medical Oncology in HemaSphere.[1] Watchful waiting is recommended for patients with...

Assessing Measurable Residual Disease Tied to Better Outcome in Multiple Myeloma
https://www.medscape.com/viewarticle/943007

Dec 22nd, 2020 - NEW YORK (Reuters Health) - Clinical decision-making based on assessment of measurable residual disease (MRD) is associated with better outcome in patients with multiple myeloma (MM), a real-world study indicates. Patients who were MRD negative, a...

Five-Minute SC Injection of Daratumumab in R/R Multiple Myeloma
https://www.medscape.com/viewarticle/942222

Dec 8th, 2020 - Data from the Apollo study provide proof for the subcutaneous administration (sc) of daratumumab (Darzalex Faspro) in combination with pomalidomide (Pomalyst) and dexamethasone (Pd) for patients with relapsed or refractory multiple myeloma (RRMM)....

Circulating miRNA for Early Diagnosis of Multiple Myeloma
https://www.medscape.com/viewarticle/941594

Nov 25th, 2020 - Circulating microRNAs (miRNAs) could be a potential noninvasive biomarker for early diagnosis of multiple myeloma (MM), according to the results of a meta-analysis published online in the Journal of Bone Oncology. In recent years, because of the r...

see more →

Patient Education  6 results see all →